Cargando…

FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism

BACKGROUND: FGF21 pharmacological treatment reverses fatty liver and lowers serum triglyceride concentration but FGF21 serum level is increased in hepatic steatosis. FGF21 secretion is induced by thyroid hormones in vitro. PURPOSE: To determine the influence of thyroid hormones and metabolic changes...

Descripción completa

Detalles Bibliográficos
Autores principales: Szczepańska, Ewa, Glinicki, Piotr, Zgliczyński, Wojciech, Słowińska-Srzednicka, Jadwiga, Jastrzębska, Helena, Gietka-Czernel, Małgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329662/
https://www.ncbi.nlm.nih.gov/pubmed/35909532
http://dx.doi.org/10.3389/fendo.2022.900034
_version_ 1784757967920300032
author Szczepańska, Ewa
Glinicki, Piotr
Zgliczyński, Wojciech
Słowińska-Srzednicka, Jadwiga
Jastrzębska, Helena
Gietka-Czernel, Małgorzata
author_facet Szczepańska, Ewa
Glinicki, Piotr
Zgliczyński, Wojciech
Słowińska-Srzednicka, Jadwiga
Jastrzębska, Helena
Gietka-Czernel, Małgorzata
author_sort Szczepańska, Ewa
collection PubMed
description BACKGROUND: FGF21 pharmacological treatment reverses fatty liver and lowers serum triglyceride concentration but FGF21 serum level is increased in hepatic steatosis. FGF21 secretion is induced by thyroid hormones in vitro. PURPOSE: To determine the influence of thyroid hormones and metabolic changes secondary to thyroid dysfunction on FGF21 secretion in humans. MATERIALS AND METHODS: This was a case-control study. 82 hyperthyroid and 15 hypothyroid patients were recruited together with 25 healthy controls. Of those with hyperthyroidism, 56 received radioiodine treatment and 42 of them achieved hypothyroidism and then euthyroidism within one year following therapy. Radioiodine-induced hypothyroidism developed abruptly within a six week interval between clinic visits. FGF21 serum levels were determined with an ELISA method. RESULTS: Serum FGF21 levels did not differ in hyper- and hypothyroid patients in comparison to controls [median 103.25 (interquartile range, 60.90-189.48) and 86.10 (54.05-251.02) vs 85.20 (58.00-116.80) pg/mL P=0.200 and 0.503, respectively]. In hyperthyroid patients treated with radioiodine, serum FGF21 levels increased significantly in rapid-onset hypothyroidism in comparison to the hyperthyroid and euthyroid phase [median 160.55 (interquartile range, 92.48 - 259.35) vs 119.55 (67.78-192.32) and 104.43 (55.93-231.93) pg/mL, P=0.034 and 0.033, respectively]. The rising serum FGF21 level correlated positively with serum triglycerides (Spearman coefficient rs=0.36, P=0.017) and inversely with serum SHBG (rs=-0.41, P=0.007), but did not correlate with thyroid hormone levels. CONCLUSIONS: There was a transient increase in FGF21 serum level during rapid-onset hypothyroidism following radioiodine treatment. There was no association between FGF21 serum level and thyroid hormones. In radioiodine-induced hypothyroidism, the rising serum FGF21 concentration correlated positively with rising serum triglycerides and negatively with falling SHBG, reflecting increased hepatic lipogenesis.
format Online
Article
Text
id pubmed-9329662
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93296622022-07-29 FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism Szczepańska, Ewa Glinicki, Piotr Zgliczyński, Wojciech Słowińska-Srzednicka, Jadwiga Jastrzębska, Helena Gietka-Czernel, Małgorzata Front Endocrinol (Lausanne) Endocrinology BACKGROUND: FGF21 pharmacological treatment reverses fatty liver and lowers serum triglyceride concentration but FGF21 serum level is increased in hepatic steatosis. FGF21 secretion is induced by thyroid hormones in vitro. PURPOSE: To determine the influence of thyroid hormones and metabolic changes secondary to thyroid dysfunction on FGF21 secretion in humans. MATERIALS AND METHODS: This was a case-control study. 82 hyperthyroid and 15 hypothyroid patients were recruited together with 25 healthy controls. Of those with hyperthyroidism, 56 received radioiodine treatment and 42 of them achieved hypothyroidism and then euthyroidism within one year following therapy. Radioiodine-induced hypothyroidism developed abruptly within a six week interval between clinic visits. FGF21 serum levels were determined with an ELISA method. RESULTS: Serum FGF21 levels did not differ in hyper- and hypothyroid patients in comparison to controls [median 103.25 (interquartile range, 60.90-189.48) and 86.10 (54.05-251.02) vs 85.20 (58.00-116.80) pg/mL P=0.200 and 0.503, respectively]. In hyperthyroid patients treated with radioiodine, serum FGF21 levels increased significantly in rapid-onset hypothyroidism in comparison to the hyperthyroid and euthyroid phase [median 160.55 (interquartile range, 92.48 - 259.35) vs 119.55 (67.78-192.32) and 104.43 (55.93-231.93) pg/mL, P=0.034 and 0.033, respectively]. The rising serum FGF21 level correlated positively with serum triglycerides (Spearman coefficient rs=0.36, P=0.017) and inversely with serum SHBG (rs=-0.41, P=0.007), but did not correlate with thyroid hormone levels. CONCLUSIONS: There was a transient increase in FGF21 serum level during rapid-onset hypothyroidism following radioiodine treatment. There was no association between FGF21 serum level and thyroid hormones. In radioiodine-induced hypothyroidism, the rising serum FGF21 concentration correlated positively with rising serum triglycerides and negatively with falling SHBG, reflecting increased hepatic lipogenesis. Frontiers Media S.A. 2022-07-14 /pmc/articles/PMC9329662/ /pubmed/35909532 http://dx.doi.org/10.3389/fendo.2022.900034 Text en Copyright © 2022 Szczepańska, Glinicki, Zgliczyński, Słowińska-Srzednicka, Jastrzębska and Gietka-Czernel https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Szczepańska, Ewa
Glinicki, Piotr
Zgliczyński, Wojciech
Słowińska-Srzednicka, Jadwiga
Jastrzębska, Helena
Gietka-Czernel, Małgorzata
FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism
title FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism
title_full FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism
title_fullStr FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism
title_full_unstemmed FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism
title_short FGF21 Is Released During Increased Lipogenesis State Following Rapid-Onset Radioiodine-Induced Hypothyroidism
title_sort fgf21 is released during increased lipogenesis state following rapid-onset radioiodine-induced hypothyroidism
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329662/
https://www.ncbi.nlm.nih.gov/pubmed/35909532
http://dx.doi.org/10.3389/fendo.2022.900034
work_keys_str_mv AT szczepanskaewa fgf21isreleasedduringincreasedlipogenesisstatefollowingrapidonsetradioiodineinducedhypothyroidism
AT glinickipiotr fgf21isreleasedduringincreasedlipogenesisstatefollowingrapidonsetradioiodineinducedhypothyroidism
AT zgliczynskiwojciech fgf21isreleasedduringincreasedlipogenesisstatefollowingrapidonsetradioiodineinducedhypothyroidism
AT słowinskasrzednickajadwiga fgf21isreleasedduringincreasedlipogenesisstatefollowingrapidonsetradioiodineinducedhypothyroidism
AT jastrzebskahelena fgf21isreleasedduringincreasedlipogenesisstatefollowingrapidonsetradioiodineinducedhypothyroidism
AT gietkaczernelmałgorzata fgf21isreleasedduringincreasedlipogenesisstatefollowingrapidonsetradioiodineinducedhypothyroidism